Lanadelumab could revolutionise treatment of swelling disease.
Biotech insists drug for rare inherited disorder is still approvable.
Could French biotech snap up remaining rights to pancreatic cancer drug?
FDA asked Mitsubishi to file Radicava following approval in Japan.
BioHaven raises $168 million with biggest biotech IPO seen this year.
Gaining access to ultra-orphan drugs could become much more difficult.
Benefitting from insights from focus groups with rare disease patients.
US insurers are covering the treatment, despite high price.
